Nanobiotix (NBTX.US), whose stock price surged by over 700% in one year, has attracted the acquisition interest of Johnson & Johnson (JNJ.US).

According to a report in the well-known French magazine "La Lettre", American pharmaceutical giant Johnson & Johnson (JNJ.US) is considering making a takeover bid. Following this news, the stock price of French cancer drug developer Nanobiotix (NBTX.US) rose by about 7% on the Paris stock exchange on Wednesday, and by over 15% in pre-market trading in the US. Based in Paris, Nanobiotix currently maintains a partnership with global healthcare leader Johnson & Johnson. According to a long-term licensing agreement signed in 2023 with the New Jersey-based pharmaceutical company Johnson & Johnson, the two companies are collaborating to develop and commercialize their next generation core asset JNJ-1900 (NBTXR3). Last October, the company's stock price surged significantly due to preliminary results from a phase I clinical trial that aimed to evaluate a tumor-injection therapy as a part of United Therapeutics Corporation's program for advanced esophageal adenocarcinoma. In the last year of 2025, Nanobiotix's stock price and market value have increased by over 700%, reaching a market value of approximately $1.5 billion. Nanobiotix is essentially a late-stage clinical oncology biotech company based in France, focusing on a "physics-driven nano-therapeutic platform" rather than traditional small molecule or antibody drugs. Its most important core asset is NBTXR3/JNJ-1900, a candidate product composed of functionalized hafnium oxide nanoparticles that, when injected into a tumor once, enhance energy deposition within the tumor under radiotherapy, improving the efficiency of killing tumor cells while minimizing radiation damage to surrounding normal tissues. The company's main business is centered around this "radiotherapy sensitization/radiotherapy enhancement" platform, advancing clinical development in several solid tumors such as head and neck cancer, lung cancer, esophageal cancer, and pancreatic cancer, and aiming to make it a fundamental technology for tumor treatment that can be extended across cancer types. The company has continuously released positive clinical signals in 2025, which is the core logic behind the 700% increase in its stock price in the past year; for example, initial data for esophageal cancer showed good treatment tolerance, with an 85% disease control rate and a 69% objective response rate among 13 patients; the company is also progressing in indications such as pancreatic cancer and lung cancer. In 2023, Janssen, a subsidiary of Johnson & Johnson, signed a global co-development and commercialization licensing agreement with Nanobiotix. In March 2025, the two parties revised the agreement, relieving Nanobiotix of the financial obligations for the pivotal phase III head and neck cancer study NANORAY-312, and extending the cash runway until mid-2026. This move significantly alleviates the most fatal financing pressure for clinical-stage biotech companies. If the JNJ-1900 asset or the phase III head and neck cancer data continue to show positive results, a direct acquisition by Johnson & Johnson would be more advantageous in terms of gaining global rights, pricing power, and future indication expansions than a long-term revenue split. In other words, what attracts Johnson & Johnson to Nanobiotix is not just a single product, but the potential behind its physical nano-therapeutic platform that could be magnified into a new paradigm for enhancing tumor radiotherapy.